Welcome to our dedicated page for Erasca SEC filings (Ticker: ERAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Erasca, Inc. (NASDAQ: ERAS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage precision oncology issuer. Erasca files current reports on Form 8-K and other documents with the U.S. Securities and Exchange Commission (SEC) that describe financial results, corporate actions, and governance matters.
Recent Form 8-K filings referenced by the company include announcements of quarterly financial results for periods ended June 30 and September 30, 2025, where Erasca reported research and development expenses, general and administrative expenses, and net loss figures, along with commentary on its cash, cash equivalents, and marketable securities. Another Form 8-K details the results of the company’s annual meeting of stockholders, including the election of Class I directors and ratification of its independent registered public accounting firm.
For investors analyzing ERAS, these filings complement Erasca’s press releases about its RAS-targeting franchise, including ERAS-0015 and ERAS-4001. While the scientific and clinical details are often highlighted in news announcements, SEC filings provide the formal financial and corporate context, as well as risk factor discussions in periodic reports such as the Form 10-K that the company cites in its cautionary notes.
On Stock Titan, users can review Erasca’s SEC filings as they are made available through EDGAR and use AI-powered summaries to understand key points from lengthy documents, including earnings-related 8-Ks and proxy-related disclosures. This helps readers connect the company’s financial condition and governance decisions with its ongoing efforts to develop therapies for RAS/MAPK pathway-driven cancers.
Erasca, Inc. Form 144 filing notifies proposed sales of Common stock by the Erasca Foundation as reported on the form. The filing lists multiple entries with a recurring figure 8333 associated with each sale line and transaction dates such as 02/17/2026, 01/15/2026, and 12/15/2025.
Examples shown include Erasca Foundation entries dated 02/17/2026 (8333) and 01/15/2026 (8333). The filing identifies Nasdaq as the market and includes an apparent reporting date of 03/16/2026.
Erasca, Inc. files its annual report describing a focused strategy to develop precision oncology drugs that shut down the RAS/MAPK pathway in cancer. The company highlights two clinical-stage programs, ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), plus discovery-stage EGFR antibody ERAS-12.
Early Phase 1 data for ERAS-0015 show partial responses at low doses with favorable safety and linear pharmacokinetics. Erasca exercised its option to expand territorial rights for ERAS-0015 globally (including mainland China) under its Joyo license and is preparing multiple monotherapy and combination readouts in 2026–2027.
The company streamlined its portfolio by terminating several legacy programs and license agreements to concentrate resources on its RAS franchise and EGFR antibody platform. As of June 30, 2025, non-affiliate common stock held an aggregate market value of $316.4 million, and common shares outstanding totaled 310,799,547 as of March 5, 2026.
Erasca, Inc. reported fourth quarter and full year 2025 results alongside business and pipeline updates. For 2025, net loss narrowed to $124.5 million, or $(0.44) per share, from $161.7 million, or $(0.69) per share, in 2024 as operating expenses declined.
Research and development expenses fell to $92.9 million from $115.4 million, while general and administrative expenses decreased to $38.6 million from $41.7 million. Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, down from $440.5 million a year earlier.
The company completed an upsized public offering in January 2026, raising approximately $258.8 million in gross proceeds and expects pro forma cash of $434 million to fund operations into the second half of 2028. Erasca highlighted encouraging early clinical activity for ERAS-0015, continued advancement of ERAS-4001, and new U.S. composition-of-matter patents supporting its RAS-targeting franchise, with multiple Phase 1 data readouts and trial expansions planned in 2026 and 2027.
Erasca, Inc. Chief Medical Officer Morris Shannon reported an option exercise and related share sale. On March 4, 2026, he exercised options for 20,000 shares of common stock at $1.70 per share and sold 20,000 shares in open-market transactions at a weighted-average price of $15.038 per share. These transactions were carried out under a previously adopted Rule 10b5-1 trading plan. Following a related derivative entry dated March 4, 2025, he held 515,800 stock options, which vest monthly in 48 installments starting February 1, 2024, contingent on continued service.
Erasca Foundation filed notice under Rule 144 to sell 8,333 shares of Erasca, Inc. common stock through Merrill Lynch on or about 02/17/2026 on NASDAQ, with an aggregate market value of $99,245.03.
The foundation acquired 10,193,557 common shares as a donation from Erasca, Inc. on 07/20/2021. Over the past three months it has already sold 8,333 shares on each of 11/17/2025, 12/15/2025, and 01/15/2026, receiving gross proceeds of $21,626.50, $30,438.69, and $68,573.87 respectively.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 16,111,414 shares of Erasca Inc. common stock, representing 5.7% of the class as of 12/31/2025.
The firm reports sole power to vote and dispose of all 16,111,414 shares, with no shared voting or dispositive power. It states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Erasca.
Erasca, Inc. Chairman, CEO and 10% owner Jonathan E. Lim reported receiving a stock option grant covering 2,000,000 shares of common stock. The option has an exercise price of $10.31 per share and is held directly.
According to the vesting terms, 1/48 of the option shares vest each month on the 29th (or the last day of February), beginning in February 2026, so long as Lim continues to provide service to Erasca on each vesting date. After this grant, he beneficially owns options for 2,000,000 shares.
Erasca, Inc. reported insider equity activity by its CFO and CBO, David M. Chacko. On 12/15/2025, he acquired 17,793 shares of common stock at $1.1943 per share through the company’s 2021 Employee Stock Purchase Plan, bringing his directly held common shares to 279,980.
On 01/29/2026, he was granted a stock option for 640,000 shares of common stock with an exercise price of $10.31 per share. One forty-eighth of these option shares vest monthly starting in February 2026, conditioned on his continued service to Erasca.
Erasca, Inc. reported a new equity award for its Chief Medical Officer, Morris Shannon. A Form 4 shows a grant of stock options covering 625,000 shares of common stock, with an exercise price of $10.31 per share, dated January 29, 2026.
These options vest over four years: 1/48th of the shares vest each month on the 29th (or the last day of February), beginning in February 2026, as long as Shannon continues serving the company on each vesting date. All 625,000 options are reported as directly owned following this grant.